Compare Advance Auto Parts, Inc. (AAP) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Bristol-Myers Squibb Co — how do they compare? Advance Auto Parts, Inc. trades at $53.56 (market cap $3.19B), while Bristol-Myers Squibb Co trades at $63.77 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 40.7× Advance Auto Parts, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| AAP | BMY | |
|---|---|---|
Market Cap | $3.19B | $129.94B |
Sector | Consumer Cyclical | Health |
52-Week High | $64.17 | $65.89 |
52-Week Low | $38.75 | $42.60 |
Enterprise Value | $5.47B | $163.92B |
Dividend Yield | 1.89% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $53.59, down 3.84% on the day, with a bearish technical signal. Recent earnings have consistently beaten estimates, but profitability remains thin with a net margin of 0.51%. The company is executing a turnaround focused on professional sales and supply chain restructuring. Cash flow trends show heavy financing activity supporting operations.
The outlook is mixed; analyst consensus is a Buy with a $61.30 price target, but high debt and weak operating cash flow pose risks. Upside depends on successful execution of the restructuring plan to improve margins and stabilize revenue. Near-term support is at $52, with resistance at $55.
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
